Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Meshaberase LLC manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's prosecution is currently limited to 1 distinct examiner and 1 distinct art unit. This reflects a focused approach to its current patent applications within a single technical field. Such concentration can be beneficial for ensuring that the examiner develops a thorough understanding of the company's specific technical disclosures over time.
The busiest examiner for this portfolio is HUANG, GIGI GEORGIANA, who is handling 1 busiest examiner pending office action. This single action accounts for the total of 1 pending office action for the company. Because there is only 1 distinct art unit involved, all current feedback from the patent office originates from this specific examiner. This alignment allows the applicant to tailor their prosecution strategy to the specific technical requirements and preferences of 1 distinct examiner within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17119000 | USE OF CYSTEAMINE AND DERIVATIVES THEREOF TO TREAT DYSFUNCTIONAL TEAR SYNDROME (DTS) | HUANG, GIGI GEORGIANA | 30d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17119000 | USE OF CYSTEAMINE AND DERIVATIVES THEREOF TO TREAT DYSFUNCTIONAL TEAR SYNDROME (DTS) | HUANG, GIGI GEORGIANA | 30d overdue |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17119000 | USE OF CYSTEAMINE AND DERIVATIVES THEREOF TO TREAT DYSFUNCTIONAL TEAR SYNDROME (DTS) | HUANG, GIGI GEORGIANA | 1613 | §103§112 | Final Rejection | 30d overdue | Pending | Dec 11, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial